A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer - Concepedia

Concepedia

Publication | Open Access

A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer

DOI Full Paper Access

69

Citations

14

References

2020

Year

Hatem Soliman, Deanna Hogue, Hyo S. Han, Blaise Mooney, Ricardo A. Costa, Marie Catherine Lee, Bethany L. Niell, Angela Williams, Alec Chau, Shannon Falcon,

Clinical Cancer Research

Abstract

The addition of TVEC to NAC was feasible at the approved dose, with manageable toxicity. The complete response rate was 55%.

References

	Year	Citations

Page 1